Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$11.24 -5.1%	$10.41	$7.80 ▼ $28.09	$615.87M	N/A	594,215 shs	71,438 shs
FTLF FitLife Brands	$18.40 +8.2%	$14.00	$9.83 ▼ $18.48	$172.73M	0.79	20,224 shs	29,166 shs
MRVI Maravai LifeSciences	$2.41 -1.7%	$2.45	$1.66 ▼ $9.60	$611.59M	0.28	2.39 million shs	642,827 shs
SIGA Siga Technologies	$8.67 -5.1%	$7.21	$4.95 ▼ $9.62	$621.22M	0.94	477,094 shs	272,342 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	0.00%	+1.72%	+0.77%	+27.72%	+1,183,999,900.00%
FTLF FitLife Brands	0.00%	+2.35%	+31.78%	+16.60%	+3.41%
MRVI Maravai LifeSciences	0.00%	-6.13%	-8.92%	+10.36%	-72.50%
SIGA Siga Technologies	0.00%	+7.41%	+27.87%	+54.48%	-3.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FTLF FitLife Brands	3.568 of 5 stars	2.5	4.0	0.0	0.0	2.7	1.7	3.1
MRVI Maravai LifeSciences	4.0292 of 5 stars	3.1	3.0	0.0	4.4	2.9	0.8	0.6
SIGA Siga Technologies	2.3852 of 5 stars	0.0	2.0	0.0	0.0	3.2	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	3.00	Buy	$32.25	186.93% Upside
FTLF FitLife Brands	3.00	Buy	$22.00	19.60% Upside
MRVI Maravai LifeSciences	2.25	Hold	$5.75	138.79% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest FTLF, MRVI, SIGA, and BCAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$41.00 ➝ $40.00
8/18/2025	BCAX Bicara Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$36.00
8/15/2025	FTLF FitLife Brands	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $25.00
8/12/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
8/12/2025	MRVI Maravai LifeSciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$7.00 ➝ $5.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$9.04 per share	N/A
FTLF FitLife Brands	$64.47M	2.68	$1.10 per share	16.78	$3.93 per share	4.68
MRVI Maravai LifeSciences	$259.18M	2.37	$0.61 per share	3.96	$2.28 per share	1.06
SIGA Siga Technologies	$138.72M	4.47	$0.79 per share	10.91	$3.02 per share	2.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	-$68M	-$3.17	N/A	N/A	N/A	N/A	-21.67%	-20.89%	11/11/2025 (Estimated)
FTLF FitLife Brands	$8.98M	$0.84	21.90	16.72	N/A	12.63%	21.70%	13.45%	N/A
MRVI Maravai LifeSciences	-$144.85M	-$1.36	N/A	N/A	N/A	-90.03%	-17.60%	-9.30%	11/6/2025 (Estimated)
SIGA Siga Technologies	$59.21M	$1.13	7.68	6.93	N/A	45.73%	40.52%	35.62%	11/6/2025 (Estimated)

Latest FTLF, MRVI, SIGA, and BCAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FTLF FitLife Brands	$0.18	$0.18	N/A	$0.18	$16.17 million	$16.13 million
8/12/2025	Q2 2025	BCAX Bicara Therapeutics	-$0.54	-$0.50	+$0.04	-$0.50	N/A	N/A
8/5/2025	Q2 2025	SIGA Siga Technologies	N/A	$0.49	N/A	$0.49	N/A	$81.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
FTLF FitLife Brands	N/A	N/A	N/A	N/A	N/A
MRVI Maravai LifeSciences	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	25.80	25.80
FTLF FitLife Brands	0.15	1.71	0.81
MRVI Maravai LifeSciences	0.68	5.16	4.49
SIGA Siga Technologies	N/A	10.09	8.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
FTLF FitLife Brands	2.32%
MRVI Maravai LifeSciences	50.25%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	N/A
FTLF FitLife Brands	61.40%
MRVI Maravai LifeSciences	2.11%
SIGA Siga Technologies	1.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	32	54.56 million	N/A	N/A
FTLF FitLife Brands	20	9.39 million	3.63 million	Not Optionable
MRVI Maravai LifeSciences	610	255.36 million	249.97 million	Optionable
SIGA Siga Technologies	40	71.61 million	70.21 million	Optionable

FTLF, MRVI, SIGA, and BCAX Headlines

Recent News About These Companies

Siga Technologies Sees Unusually Large Options Volume (NASDAQ:SIGA)

August 23 at 4:04 AM | marketbeat.com

First Wilshire Securities Management Inc. Has $8.70 Million Stock Position in Siga Technologies Inc. $SIGA

August 21, 2025 | marketbeat.com

SIGA Technologies: Still Bullish, But Worth Trimming Ahead Of BARDA News

August 20, 2025 | seekingalpha.com

Siga Technologies (NASDAQ:SIGA) Trading Down 4.9% - Should You Sell?

August 15, 2025 | marketbeat.com

Wall Street Zen Upgrades Siga Technologies (NASDAQ:SIGA) to Strong-Buy

August 10, 2025 | marketbeat.com

SIGA Technologies Second Quarter 2025 Earnings: EPS: US$0.50 (vs US$0.026 in 2Q 2024)

August 8, 2025 | finance.yahoo.com

Siga Technologies (NASDAQ:SIGA) Trading 13.9% Higher - Here's Why

August 7, 2025 | marketbeat.com

SIGA (SIGA) Q2 Revenue Soars 272%

August 7, 2025 | theglobeandmail.com

Siga Technologies (NASDAQ:SIGA) Issues Earnings Results

August 6, 2025 | marketbeat.com

SIGA Technologies (SIGA) Reports Significant Earnings Decline

August 6, 2025 | finance.yahoo.com

SIGA advances pediatric and PEP programs as product revenues reach $79M, supported by new BARDA funding

August 6, 2025 | msn.com

SIGA Technologies, Inc. (SIGA) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

August 5, 2025 | globenewswire.com

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

July 29, 2025 | globenewswire.com

Royce & Associates LP Has $4.16 Million Holdings in Siga Technologies Inc. (NASDAQ:SIGA)

July 28, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Stock Falls Amid Market Uptick: What Investors Need to Know

July 24, 2025 | zacks.com

Siga Technologies Inc. (SIGA) Dips More Than Broader Market: What You Should Know

July 15, 2025 | msn.com

US Market's Undiscovered Gems Featuring Three Promising Small Caps

July 15, 2025 | finance.yahoo.com

Siga Technologies Inc. (SIGA) Laps the Stock Market: Here's Why

July 9, 2025 | zacks.com

SIGA Technologies Inc Dividends - Morningstar

July 8, 2025 | morningstar.comM

Why Siga Technologies Inc. (SIGA) Outpaced the Stock Market Today

June 26, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTLF, MRVI, SIGA, and BCAX Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$11.24 -0.60 (-5.07%)

As of 03:47 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

FitLife Brands NASDAQ:FTLF

$18.40 +1.40 (+8.21%)

As of 03:43 PM Eastern

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

Maravai LifeSciences NASDAQ:MRVI

$2.41 -0.04 (-1.71%)

As of 03:47 PM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Siga Technologies NASDAQ:SIGA

$8.66 -0.47 (-5.09%)

As of 03:47 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time